The role of cytochrome P4502E1 in ethanol mediated diseases: a narrative update.
Level 5 - mechanism / opinion, no new human data
Narrative review summarizing mechanistic, preclinical, and clinical literature
PubMed 40192654 · doi:10.1093/alcalc/agaf014
What was done
This narrative review summarizes literature regarding the mechanistic and pathological roles of cytochrome P4502E1 (CYP2E1) in ethanol metabolism, alcohol-associated liver disease (AALD), and alcohol-mediated cancer (AMC), including evidence from cell culture, animal models, and clinical studies.
What was found
The abstract reports no quantitative values or statistical metrics. Qualitatively, chronic ethanol induces CYP2E1, increasing reactive oxygen species (ROS) production, lipid peroxidation products, etheno-DNA adducts, and procarcinogen activation, while depleting hepatic retinol and retinoic acid. Preclinical models showed that CYP2E1 knockout or chemical inhibition improved liver histology and reduced steatosis and fibrosis. In clinical studies of patients with AALD, CYP2E1 inhibition via clomethiazole improved serum transaminase activities.
Why it matters
It outlines the central mechanistic role of CYP2E1 in ethanol-induced tissue injury and highlights CYP2E1 inhibition as a potential therapeutic avenue for alcohol-related liver damage and carcinogenesis.
Limits
As a narrative review, it lacks systematic search methodology, risk-of-bias assessment, and quantitative meta-analysis. The abstract reports no sample sizes, effect sizes, statistical measures, or safety profiles for CYP2E1 inhibitors such as clomethiazole.
Cited by
- supports Heavy alcohol consumption increases the activity of the enzyme CYP2E1, which oxidizes ethanol to acetaldehyde and generates reactive oxygen species.